ABT vs BSX
Abbott Laboratories and Boston Scientific, side by side.
Prices and company dataas of yesterday's close
- ABTKeep2.3%
Abbott Laboratories pays a 2.3% dividend that it has raised for 54 years in a row, but the stock fell 5.3% over the past five trading days, in step with other medical device makers (down 4.7%).
- BSXBuy moresales growth, past year8.9%
Boston Scientific's sales grew 8.9% over the past year, but it sits 57% below its high of the past year.
Percent return
- ABT−11.81%
- BSX−55.97%
Nov 11, 2025 to Nov 11, 2026
Where they differ
- Company size: ABT $174B, BSX $68.5B.
- Sales growth, 1 yr: ABT +10%, BSX +8.9%. ABT is ahead.
- Price for $1 of next year's profit: ABT $19, BSX $14. BSX is ahead.
- Profit per $1 of sales: ABT 16¢, BSX 20¢. BSX is ahead.
- Cash minus debt: ABT −$27.1B, BSX −$11.3B. BSX is ahead.
- Price change, 1 yr: ABT −12%, BSX −56%. ABT is ahead. S&P 500 +12%.
- How much the price swings: ABT 30%, BSX 37%. ABT is ahead.
| Measure | ABTAbbott Laboratories | BSXBoston Scientific |
|---|---|---|
| Price and returns | ||
| Price | $109.35 | $45.15 |
| Today | −1.00% | Best in this row: +1.00% |
| 1 month | Best in this row: +10.40% | +5.62% |
| 3 months | Best in this row: +0.28% | −11.81% |
| This year | Best in this row: −10.60% | −52.67% |
| 1 year | Best in this row: −11.81% | −55.97% |
| 5 years | −5.13% | Best in this row: +7.55% |
| From 52-week high | −14.2% | −57.0% |
| How much it swings (90 days) | Best in this row: 30% | 37% |
| Valuation | ||
| Market value | $174B | $68.5B |
| Price vs last year's earnings | 32.3× | Best in this row: 19.3× |
| Price vs next year's expected earnings | 18.8× | Best in this row: 13.9× |
| Price vs earnings, adjusted for growth | 1.65× | Best in this row: 1.12× |
| Price to sales | 4.0× | Best in this row: 2.9× |
| Price vs cash it brings in | 28.2× | Best in this row: 18.6× |
| Company value vs operating profit | 19.0× | Best in this row: 13.2× |
| Growth | ||
| Revenue growth, 1 year | Best in this row: +10.0% | +8.9% |
| Revenue growth a year, last 3 years | +0.5% | Best in this row: +16.5% |
| Earnings per share growth, last year | −53.4% | Best in this row: +74.4% |
| Earnings per share growth expected next year | Best in this row: +7.6% | −1.1% |
| Profitability | ||
| Kept from sales after making the product | 57.2% | Best in this row: 68.0% |
| Kept as operating profit | 15.7% | Best in this row: 19.6% |
| Kept as final profit | 9.7% | Best in this row: 16.6% |
| Kept as spare cash | 14.0% | Best in this row: 15.8% |
| Profit on shareholders' money | 9.1% | Best in this row: 14.1% |
| Profit on all money put in | 6.9% | Best in this row: 10.6% |
| Balance sheet | ||
| Net cash (cash minus debt) | −$27.1B | Best in this row: −$11.3B |
| Debt for each $1 of shareholders' money | 0.61× | Best in this row: 0.46× |
| Short-term assets per $1 of bills due | Best in this row: 1.45× | 1.36× |
| Dividend yield | 2.29% | – |
| Share of profit paid as dividends | 94% | – |
| Our readPro | ||
| Our call | Keep | Buy more |
| Why | Abbott Laboratories pays a 2.3% dividend that it has raised for 54 years in a row, but the stock fell 5.3% over the past five trading days, in step with other medical device makers (down 4.7%). | Boston Scientific's sales grew 8.9% over the past year, but it sits 57% below its high of the past year. |
| Where the price sits | in the full report | in the full report |
| Our overall score (out of 100) | 57 | Best in this row: 73 |
| Our value score | 82 | Best in this row: 96 |
| Our growth score | 33 | Best in this row: 76 |
| Our quality score | 68 | Best in this row: 75 |
| Our price trend score | Best in this row: 63 | 50 |
| Earnings and analysts | ||
| Analyst consensus | Buy | Buy |
| To average analyst target | Best in this row: +11.5% | +10.9% |
| Average analyst target | $121.94 | $50.05 |
| Analysts rating it a buy | Best in this row: 82% | 61% |
| Buy ratings added, 3 months | Best in this row: +2 | −7 |
| Analysts covering | 17 | 22 |
BSX: our only Buy more of these
Our pick of these: Boston Scientific
Forward P/E per point of sales growth 1.56 vs 1.88
ABT 1.88, BSX 1.56.Keeps 19.6% of sales as operating profit, vs 15.7%
ABT 15.7%, BSX 19.6%.Where it loses: ABT has a better past year, −11.8% vs −56.0%
Cover this stock to see the full report
The call, its reasons and what would change it are free for everyone. The price zones, the whole brief and how the call has moved come with covering a stock. Use one of your three covered slots, or go Pro for every stock.
Prices as of yesterday, 3:59 PM ET. A view, not advice.